Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | G128D |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 G128D lies within the protein kinase domain of the Map2k1 protein (UniProt.org). G128D confers a gain of function to the Map2k1 protein as indicated by increased Erk phosphorylation in culture (PMID: 28115009, PMID: 25899310, PMID: 34726260). |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 G128D |
Transcript | NM_002755.4 |
gDNA | chr15:g.66436837G>A |
cDNA | c.383G>A |
Protein | p.G128D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002755.3 | chr15:g.66436837G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66436837G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66436837G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66436837G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66444666G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66444666G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66436837G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66444666G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66436837G>A | c.383G>A | p.G128D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 G128D | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and decreased cell size in a cell line expressing MAP2K1 G128D (PMID: 34726260). | 34726260 |
MAP2K1 G128D | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 G128D in culture (PMID: 36442478). | 36442478 |